Coronavirus disease 2019 (COVID-19): Secondary bacterial infections and the impact on antimicrobial resistance during the COVID-19 pandemic DOI Creative Commons

Yelena Markovskaya,

Elizabeth M. Gavioli, Jaclyn A. Cusumano

и другие.

Antimicrobial Stewardship & Healthcare Epidemiology, Год журнала: 2022, Номер 2(1)

Опубликована: Янв. 1, 2022

Abstract Secondary bacterial infections and coinfections are an important complication of coronavirus disease 2019 (COVID-19), leading to antibiotic overuse increased rates antimicrobial resistance (AMR) during the COVID-19 pandemic. In this literature review, we summarize reported secondary in patients with COVID-19, impact on patient outcomes, treatment approaches employed, patterns observed. The data suggest that although incidence or is relatively low, they associated worse outcomes such as prolonged hospitalization, intensive care unit admission, mechanical ventilator use, mortality. Interestingly, prescription typically higher than coinfection rates, reports AMR common. These findings highlight need for improved understanding well options, mitigate inappropriate prescribing AMR.

Язык: Английский

Mucormycosis in Indian COVID-19 Patients: Insight into Its Patho-Genesis, Clinical Manifestation, and Management Strategies DOI Creative Commons
Ram Kumar Sahu, Mounir M. Salem‐Bekhit, Bedanta Bhattacharjee

и другие.

Antibiotics, Год журнала: 2021, Номер 10(9), С. 1079 - 1079

Опубликована: Сен. 6, 2021

Mucormycosis in patients who have COVID-19 or are otherwise immunocompromised has become a global problem, causing significant morbidity and mortality. Infection is debilitating fatal, leading to loss of organs emotional trauma. Radiographic manifestations not specific, but diagnosis can be made through microscopic examination materials collected from necrotic lesions. Treatment requires multidisciplinary expertise, as the fungus enters eyes nose may even reach brain. Use many antifungal drugs available limited by considerations resistance toxicity, nanoparticles overcome such limitations reducing toxicity increasing bioavailability. The lipid formulation amphotericin-B (liposomal Am-B) first-line treatment for mucormycosis patients, its high cost low availability prompted shift toward surgery, so that surgical debridement remove all lesions remains hallmark effective COVID-19. This review highlights pathogenesis, clinical manifestation, management

Язык: Английский

Процитировано

24

Co-infections in COVID-19 patients and correlation with mortality rate. Minireview DOI Creative Commons

Ágnes Fehér,

Z Szarvas,

Andrea Lehoczki

и другие.

Physiology International, Год журнала: 2022, Номер 109(1), С. 1 - 8

Опубликована: Фев. 25, 2022

The goal of our review was to gather information on the most important community-acquired and hospital-acquired co-infections among coronavirus disease 2019 (COVID-19) patients, examine not only effect these outcomes but also identify possible risk factors that predispose COVID-19 patients co-infections.

Язык: Английский

Процитировано

19

Antifungal Effect of Nanoparticles against COVID-19 Linked Black Fungus: A Perspective on Biomedical Applications DOI Open Access
Sangiliyandi Gurunathan,

Ah Reum Lee,

Jin‐Hoi Kim

и другие.

International Journal of Molecular Sciences, Год журнала: 2022, Номер 23(20), С. 12526 - 12526

Опубликована: Окт. 19, 2022

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible and pathogenic that has caused ‘coronavirus disease 2019’ (COVID-19) pandemic in multiple waves, which threatens human health public safety. During this pandemic, some patients with COVID-19 acquired secondary infections, such as mucormycosis, also known black fungus disease. Mucormycosis serious, acute, deadly fungal infection by Mucorales-related species, it spreads rapidly. Hence, prompt diagnosis treatment are necessary to avoid high mortality morbidity rates. Major risk factors for include uncontrolled diabetes mellitus immunosuppression can facilitate increases mucormycosis infections. The extensive use of steroids prevent the worsening lead infection. Generally, antifungal agents dedicated medical applications must be biocompatible, non-toxic, easily soluble, efficient, hypoallergenic. They should provide long-term protection against growth. COVID-19-related causes severe increase fatalities. Therefore, there strong need development novel efficient antimicrobial agents. Recently, nanoparticle-containing products available market have been used bacterial growth, but little about their efficacy respect preventing especially fungus. present review focuses on effect various types metal nanoparticles, specifically those containing silver, zinc oxide, gold, copper, titanium, magnetic, iron, carbon, growth fungi. We particularly focused how these nanoparticles impact discussed co-infection context global outbreak, management guidelines help control COVID-19-associated Finally, aimed elucidate relationship between mucormycosis.

Язык: Английский

Процитировано

19

Bacterial and Fungal Coinfection in Critically Ill COVID-19 Cases and Predictive Role of Procalcitonin During the First Wave at an Academic Health Center DOI Creative Commons

Amani Alnimr,

Mohammed Alshahrani, Sara Alwarthan

и другие.

Journal of Epidemiology and Global Health, Год журнала: 2022, Номер 12(2), С. 188 - 195

Опубликована: Апрель 9, 2022

Abstract Background Coinfection at various sites can complicate the clinical course of coronavirus disease 2019 (COVID-19) patients leading to worse prognosis and increased mortality. We aimed investigate occurrence coinfection in critically ill COVID-19 cases, predictive role routinely tested biomarkers on admission for Methods This is a retrospective study all SARS-CoV-2-infected who were admitted King Fahad Hospital University between March 2020 December 2020. reviewed data electronic charts healthcare information management system including initial presentation, course, radiological laboratory findings reported significant microbiological cultures that indicated antimicrobial therapy. The mortality severely critical care units. Results Of 1091 patients, there 70 fatalities (6.4%). 182 persons service, whom 114 (62.6%) survived. in-hospital was 13.4%. noted 67/68 non-survivors, Gram-negative pathogens ( Enterobacterales , Pseudomonas aeruginosa Acinetobacter baumanni) represented more than 50% etiological agents. serum procalcitonin higher non-survivors (Median = 1.6 ng/mL ± 4.7) survivors 0.2 4.2) p ≤ 0.05). Conclusion serious complication especially presence co-morbidities. High levels may predict non-survival cases bacterial or fungal co-infection likely.

Язык: Английский

Процитировано

17

Coronavirus disease 2019 (COVID-19): Secondary bacterial infections and the impact on antimicrobial resistance during the COVID-19 pandemic DOI Creative Commons

Yelena Markovskaya,

Elizabeth M. Gavioli, Jaclyn A. Cusumano

и другие.

Antimicrobial Stewardship & Healthcare Epidemiology, Год журнала: 2022, Номер 2(1)

Опубликована: Янв. 1, 2022

Abstract Secondary bacterial infections and coinfections are an important complication of coronavirus disease 2019 (COVID-19), leading to antibiotic overuse increased rates antimicrobial resistance (AMR) during the COVID-19 pandemic. In this literature review, we summarize reported secondary in patients with COVID-19, impact on patient outcomes, treatment approaches employed, patterns observed. The data suggest that although incidence or is relatively low, they associated worse outcomes such as prolonged hospitalization, intensive care unit admission, mechanical ventilator use, mortality. Interestingly, prescription typically higher than coinfection rates, reports AMR common. These findings highlight need for improved understanding well options, mitigate inappropriate prescribing AMR.

Язык: Английский

Процитировано

17